Relative amounts of liver Hamp and Rgmc mRNA after administration of iron, erythropoietin, or LPS
Treatment . | Hamp mRNA, % of control . | Rgmc mRNA, % of control . |
|---|---|---|
| Iron, 1 wk | 484 ± 26* | 87 ± 16 |
| Iron, 3 wks | 408 ± 91* | 79 ± 48 |
| Erythropoietin | 3 ± 2* | 81 ± 19 |
| LPS, 90 min | 166 ± 66 | 53 ± 20 |
| LPS, 6 h | 128 ± 25 | 1 ± 1* |
Treatment . | Hamp mRNA, % of control . | Rgmc mRNA, % of control . |
|---|---|---|
| Iron, 1 wk | 484 ± 26* | 87 ± 16 |
| Iron, 3 wks | 408 ± 91* | 79 ± 48 |
| Erythropoietin | 3 ± 2* | 81 ± 19 |
| LPS, 90 min | 166 ± 66 | 53 ± 20 |
| LPS, 6 h | 128 ± 25 | 1 ± 1* |
Iron was administered as a single 600-mg/kg dose 1 or 3 weeks prior to death, erythropoietin as a 50-U daily dose for 4 days preceding the day of death, and LPS as a single 1-mg/kg dose 90 minutes or 6 hours prior to death. Data are expressed as means ± SD (n = 4).
Statistically significant compared to control group (P < .05)